Pharmafile Logo
Pharmafocus logo
Advanced Search

Yervoy

Showing 11 posts of 56 posts found.

Zelboraf image

NICE still minded not to recommend Zelboraf

August 9, 2012
Sales and Marketing BMS, NICE, QALY, Yervoy, Zelboraf

NICE is asking Roche for more information about its melanoma pill Zelboraf, saying it is still too expensive and its …

News
immatics image

immatics’ vaccine increases survival in kidney cancer

July 30, 2012
Research and Development, Sales and Marketing IMA901, Vaccine, Yervoy, immatics, phase III

immatics’ investigational cancer vaccine has increased survival rates in patients with renal cell carcinoma. In a late-stage trial, the German …

News
yervoy image

Scottish watchdog rejects Yervoy

May 14, 2012
Sales and Marketing BMS, Cancer, NICE, SMC, Yervoy, melanoma

The Scottish Medicines Consortium is not recommending Bristol-Myers Squibb’s melanoma treatment Yervoy.  The SMC said that Yervoy (ipilimumab), which has …

News
Zelboraf image

Roche’s melanoma pill launched in UK

March 14, 2012
Sales and Marketing BMS, CDF, NICE, Roche, Yervoy, Zelboraf

Roche’s Zelboraf has been launched in the UK to treat the deadliest form of skin cancer.  Zelboraf (vemurafenib) is the …

News
Zelboraf image

European approval for Roche’s Zelboraf

February 20, 2012
Sales and Marketing Cancer, Roche, Yervoy, Zelboraf, melanoma

Roche’s skin cancer pill Zelboraf has been given European approval to treat advanced melanoma.  Zelboraf (vemurafenib) is now available in …

News
Gilenya picture

Key product launches of 2011

December 19, 2011
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products

 Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …

Feature
Yervoy

NICE: Bristol-Myers Squibb’s Yervoy too costly

October 14, 2011
Sales and Marketing NICE, Yervoy

Bristol Myers Squibb has failed to win NICE backing for its melanoma drug Yervoy after the Institute judged its £80,000 …

News
Yervoy (ipilimumab)

BMS launches skin cancer treatment Yervoy in UK

August 22, 2011
Sales and Marketing Yervoy, cancer vaccine, ipilimumab, skin cancer

Bristol-Myers Squibb’s skin cancer treatment Yervoy has been launched in the UK for patients with the deadliest form of the …

News
Roche

Roche’s Zelboraf approved by FDA months ahead of schedule

August 18, 2011
Sales and Marketing Yervoy, Zelboraf, skin cancer

The FDA has approved Roche and Daiichi Sankyo’s new skin cancer drug Zelboraf two months ahead of schedule. Zelboraf (vemurafenib) …

News

European approval for BMS skin cancer vaccine

July 14, 2011
Sales and Marketing BMS, Yervoy, ipilimumab

Bristol-Myers Squibb’s skin cancer vaccine Yervoy has been approved in Europe after showing survival benefits in one of the most …

News

CHMP roundup

May 24, 2011
Sales and Marketing CHMP, EMA, Fampyra, Vibativ, Victrelis, Xgeva, Yervoy

The latest products to be recommended for European approval include MSD’s Victrelis, Astellas Pharma Europe’s Vibativ, Amgen Europe’s Xgeva and …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024